Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jimmy Ren

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Cardiovascular Diabetology|March 1, 2017
Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysisMichael Pfeifer, Raymond R Townsend, Michael J Davies, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|April 22, 2016
Response to StavropoulosRaymond R Townsend, Israel Machin, Jimmy Ren, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|December 15, 2015
Reductions in Mean 24-Hour Ambulatory Blood Pressure After 6-Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and HypertensionRaymond R Townsend, Israel Machin, Jimmy Ren, et al.
IEEE Transactions on Pattern Analysis and Machine Intelligence|January 30, 2020
Physics-Based Generative Adversarial Models for Image Restoration and BeyondJinshan Pan, Jiangxin Dong, Yang Liu, et al.
Metabolism: Clinical and Experimental|February 17, 2018
Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetesW Timothy Garvey, Luc Van Gaal, Lawrence A Leiter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2022
Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)Jian-Qing Mi, Wanhong Zhao, Hongmei Jing, et al.
Diabetes|December 29, 2005
Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db miceThomas Harrity, Dennis Farrelly, Aaron Tieman, et al.
Journal of Medicinal Chemistry|March 18, 2005
Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activitiesPratik V Devasthale, Sean Chen, Yoon Jeon, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Cardiovascular Diabetology|March 1, 2017
Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysisMichael Pfeifer, Raymond R Townsend, Michael J Davies, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|April 22, 2016
Response to StavropoulosRaymond R Townsend, Israel Machin, Jimmy Ren, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|December 15, 2015
Reductions in Mean 24-Hour Ambulatory Blood Pressure After 6-Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and HypertensionRaymond R Townsend, Israel Machin, Jimmy Ren, et al.
IEEE Transactions on Pattern Analysis and Machine Intelligence|January 30, 2020
Physics-Based Generative Adversarial Models for Image Restoration and BeyondJinshan Pan, Jiangxin Dong, Yang Liu, et al.
Metabolism: Clinical and Experimental|February 17, 2018
Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetesW Timothy Garvey, Luc Van Gaal, Lawrence A Leiter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2022
Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)Jian-Qing Mi, Wanhong Zhao, Hongmei Jing, et al.
Diabetes|December 29, 2005
Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db miceThomas Harrity, Dennis Farrelly, Aaron Tieman, et al.
Journal of Medicinal Chemistry|March 18, 2005
Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activitiesPratik V Devasthale, Sean Chen, Yoon Jeon, et al.
Pageof 1